Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.88)
# 1,555
Out of 5,182 analysts
44
Total ratings
39.39%
Success rate
58.39%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $30 | $5.84 | +413.70% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $10.77 | +67.13% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $10.63 | +41.11% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.65 | +1,051.52% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $12.23 | +145.30% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $3.80 | +478.95% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $6.24 | +284.62% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $15.94 | +684.19% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.25 | +700.00% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.12 | +796.23% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.80 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $174.96 | -54.75% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $30.36 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.28 | +662.20% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $4.50 | +39,900.00% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $33.67 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.22 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.66 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.84 | +52,716.90% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.26 | +71,328.57% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.49 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $24.57 | +571.55% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.99 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.41 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $30
Current: $5.84
Upside: +413.70%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $10.77
Upside: +67.13%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $10.63
Upside: +41.11%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.65
Upside: +1,051.52%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $12.23
Upside: +145.30%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $3.80
Upside: +478.95%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $6.24
Upside: +284.62%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $15.94
Upside: +684.19%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.25
Upside: +700.00%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.12
Upside: +796.23%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.80
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $174.96
Upside: -54.75%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $30.36
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.28
Upside: +662.20%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $4.50
Upside: +39,900.00%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $33.67
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.22
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.66
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.84
Upside: +52,716.90%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.26
Upside: +71,328.57%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.49
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $24.57
Upside: +571.55%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.99
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.41
Upside: -